English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Studies  of genetic mutations that have been used in predicting glioma prognosis have  revealed a complex relationship between clinical and genetic factors. Epidermal  growth factor (EGF) and the NAT2 gene play a central role in  carcinogenesis. An adenine (A) to guanine (G) single nucleotide polymorphism at  position 61 in the 5'-untranslated region (5'-UTR) of the EGF gene has  been found to be associated with levels of EGF production, and the mutations in  the NAT2 gene have been postulated as a risk factor for cancer. We  investigated EGF and the NAT2 gene in 13 glioma tissue samples and 12  normal controls. In the EGF 5'-UTR 61G polymorphism, the heterozygote GA  was the most common genotype in the glioma patients. In the NAT2 polymorphism  at nucleotide position 857G/A, the G allele and the GG genotype were the most  prevalent forms in both the glioma and normal samples. We did not find any  homozygous AA genotypes in the glioma patients. Based on this preliminary  evidence, the EGF 5'-UTR at position 61 and the NAT2 SNP at  position 857 polymorphisms are associated with increased risk for glioma.

Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients